JERUSALEM, Sept. 14, 2020 /PRNewswire/ -- Intec Pharma Ltd.
(NASDAQ: NTEC) ("Intec" or "the Company") today announces that the
Company management will present at the virtual Oppenheimer Fall
Healthcare Life Sciences & MedTech Summit.
Oppenheimer Fall Healthcare Life Sciences & MedTech
Date: September 21 – 23, 2020
Company Presentation: Monday, September
21, 2020 at 2:30 pm (ET)
Presenter: Jeffrey A. Meckler,
Vice Chairman and Chief Executive Officer of Intec Pharma
Format: Fireside Chat and One-on-One Investor Meetings
Mr. Meckler's fireside chat will be webcast live and will be
accessible through the Events section of Intec
Pharma's website at www.intecpharma.com, where it will
also be archived for a period of time.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is in late-stage Phase 3 development for the
treatment of Parkinson's disease symptoms in advanced Parkinson's
disease patients, and AP-cannabinoids, an Accordion Pill to deliver
either or both of the primary cannabinoids contained in Cannabis
sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for
various pain indications. In addition, the Company has a research
collaboration with Merck & Co.
For more information, visit www.intecpharma.com. Intec
Pharma routinely posts information that may be important to
investors in the Investor Relations section of its website.
Intec Pharma Investor Contact:
SOURCE Intec Pharma Ltd.